GH Research Locks in $111 Million at $18 a Share, Betting on Psychedelic Breakthroughs

---

GH Research PLC, the Ireland‑incorporated biotech that has been courting hedge‑fund attention for its psychedelic pipeline, announced the pricing of its underwritten public offering on April 29, 2026. The final prospectus supplement (Form 424B5) confirms that 6,527,779 ordinary shares were sold at $18.00 per share, generating $117.5 million in gross proceeds. After the underwriters’ discount of $0.90 per share – a total of $5.875 million – the company expects $111.6 million in net proceeds before expenses.

The syndicate leading the deal consists of UBS, RBC Capital Markets, Canaccord Genuity, and Stifel, a blend of global and boutique banks that have been active in recent life‑science financings. The filing does not disclose an overallotment (greenshoe) option, meaning the offering is capped at the 6.5 million shares listed in the supplement.

Pricing versus the preliminary range The prospectus supplement does not restate the price range set in GH Research’s earlier registration statement, so a direct comparison is unavailable. Nonetheless, the $18 price point sits at the top end of the typical $16‑$18 range observed in comparable biotech offerings, suggesting that demand was strong enough to support the higher valuation.

Use of proceeds – a blank slate Unlike many biotech filings that earmark funds for specific trials or acquisitions, GH Research’s supplement provides no detailed allocation of the proceeds. The company merely notes that the net proceeds will be used for corporate purposes, leaving investors to infer that the cash will likely fund ongoing clinical work on its lead candidates (GH001, GH002) and any near‑term regulatory or partnership activities.

Risk factors that matter now The filing highlights several material risks that accompany the financing: - Immediate dilution – the offering price is substantially above the company’s net tangible book value, meaning existing shareholders will see a sizable dilution of ownership. - Potential future dilution – the prospectus warns that additional share issuances at prices below $18 could further erode shareholder value. - Absence of a greenshoe – without an overallotment option, the company cannot tap extra capital if demand exceeds expectations, which could limit flexibility. - Share‑price volatility – the company’s ordinary shares have historically been highly volatile, a risk amplified by the nascent nature of psychedelic therapeutics. - Clinical‑trial outcomes – any adverse data from GH001, GH002, or partner trials could instantly depress the stock.

Market context and analyst sentiment GH Research’s pricing comes at a time when the broader biotech market is cautiously optimistic about psychedelic medicines. Recent coverage by RBC Capital and hedge‑fund rankings placed GH Research among the top‑six promising psychedelic stocks, citing “long‑term sales potential” after a recent symposium. While the filing itself does not contain analyst forecasts, the external buzz suggests that investors view the $18 price as a fair entry point into a sector that has seen recent headline‑making deals, such as COMPASS Pathways’ post‑presidential‑order rally.

The $111 million haul positions GH Research to advance its pipeline without immediate reliance on additional debt or equity raises. However, the lack of a detailed use‑of‑proceeds narrative leaves a question mark over how the cash will be allocated across R&D, regulatory filings, or potential partnership negotiations.

In short, the offering’s pricing confirms that the market still rewards speculative bets on psychedelic breakthroughs, but the company’s next moves—clinical readouts, partnership deals, and strategic spend—will determine whether the financing translates into sustainable shareholder value.

---